About Subhasree Kar
Subhasree’s keen interest in financial instruments led her to pursue a career as an investment analyst. After earning a Master’s degree in Economics, she gained knowledge of equity research and portfolio management at Finlatics.
She uses her knowledge as a fundamental analyst to help investors make informed decisions in regards to their investment portfolios.
Recent Articles By Subhasree Kar
A10 Networks (ATEN) Stock Analysis: To Buy or Not to Buy This Tech Stock?
Networking solutions provider A10 Networks (ATEN) has steadily improved in its most recent quarter. Will the company be able to sustain its performance in the coming quarters? Let’s analyze some of its key financial metrics to gauge its prospects...
General Electric (GE) – Buy or Wait?
General Electric (GE) is experiencing robust demand amid the aviation boom. While the company’s prospects look promising, let’s analyze whether GE is a Buy or Wait at the moment...
Is Investing in General Motors (GM) a Wise Decision in the Current Environment?
As United Auto Workers union prepares to strike at Detroit automakers, will it be wise to buy General Motors (GM) shares today? Read on...
Moderna (MRNA) Stock Analysis: Is the Biotech Stock a Buy at This Time?
Biotech company Moderna (MRNA) recently published positive data from its latest flu vaccine trial, garnering investors’ attention. While the company focusing on expanding its product portfolio, is this the right time to invest in its stock? Keep reading...
Is Tesla (TSLA) Still a Solid Buy on Wall Street This Week?
Morgan Stanley analysts recently upgraded Tesla’s (TSLA) stock, citing the potential of the supercomputer that the company is developing. So, should you scoop up the electric vehicle (EV) maker’s shares this week? Read on...
Prescribe to Profits With These 3 Pharma Stocks
The pharma industry looks well-positioned for solid growth in the long term amid the rising incidence of chronic illnesses and technological advancements. So, quality pharma stocks, Eli Lilly and Company (LLY), Merck & Co. (MRK), and Teva Pharmaceutical (TEVA) could be profitable investments. Read on...
September Buy, Sell or Hold for This Pharma Sock: Catalyst Pharmaceuticals (CPRX)
Catalyst Pharmaceuticals (CPRX) delivered a robust performance in its last reported quarter. So, is now the right entry point in the stock? Let’s look at its financial metrics to gauge its prospects...
Airbnb (ABNB): Is This Travel Stock a Buy in September 2023?
While Airbnb (ABNB) is garnering investors’ attention as it is set to join the S&P 500, New York City’s crackdown on Airbnb is creating near-term uncertainties for the company. So, is ABNB worth buying now? Keep reading...
Is Flora Growth (FLGC) a Good Agriculture Stock Buy Right Now?
Flora Growth (FLGC) entered a new partnership recently to grow its presence in Europe. Moreover, as the European Union moves toward de-scheduling narcotics, is this the right time to scoop up FLGC shares? Read on...